Volker Schellenberger

Volker Schellenberger

Company: Amunix Pharmaceuticals Inc.

Job title: President & Chief Technology Officer

Bio:

Optimizing the Development & Application of HER2-Targeted Therapies in Solid Tumor Indications Outside of GI Cancer

HER2 remains one of the most validated and established oncology drug targets to date. However, a huge unmet need remains amongst patients with HER2 expressing cancers. Three recent HER2-targeted drug approvals for breast cancer, as well as exciting data from ongoing clinical trials investigating novel HER2-targeted therapies in gastric, lung, ovarian, endometrial, colon cancer, and beyond, are stimulating a new era of HER2-targeted drug development. This is being met with refreshed excitement, enthusiasm, and R&D investment for the HER2 target.

Learn more

Tuesday, November 2 – Pre-Conference Workshop 

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.